JP2010531878A - ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 - Google Patents

ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 Download PDF

Info

Publication number
JP2010531878A
JP2010531878A JP2010514839A JP2010514839A JP2010531878A JP 2010531878 A JP2010531878 A JP 2010531878A JP 2010514839 A JP2010514839 A JP 2010514839A JP 2010514839 A JP2010514839 A JP 2010514839A JP 2010531878 A JP2010531878 A JP 2010531878A
Authority
JP
Japan
Prior art keywords
human
cells
derivative
therapeutic agent
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010514839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010531878A5 (cg-RX-API-DMAC7.html
Inventor
エヌ．パブラキス ゲオルゲ
エヌ．ボウルナキス ジョフン
ケイ．フエルベル バルバラ
フインキエルスズテイン セルギオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40186225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2010531878(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2010531878A publication Critical patent/JP2010531878A/ja
Publication of JP2010531878A5 publication Critical patent/JP2010531878A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Transplantation (AREA)
JP2010514839A 2007-06-27 2008-06-27 ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用 Pending JP2010531878A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93747107P 2007-06-27 2007-06-27
PCT/US2008/008084 WO2009002562A2 (en) 2007-06-27 2008-06-27 Complexes of il-15 and il-15ralpha and uses thereof

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2014001373A Division JP2014114294A (ja) 2007-06-27 2014-01-08 ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
JP2015115431A Division JP2015212270A (ja) 2007-06-27 2015-06-08 ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用

Publications (2)

Publication Number Publication Date
JP2010531878A true JP2010531878A (ja) 2010-09-30
JP2010531878A5 JP2010531878A5 (cg-RX-API-DMAC7.html) 2011-08-11

Family

ID=40186225

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2010514839A Pending JP2010531878A (ja) 2007-06-27 2008-06-27 ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
JP2014001373A Pending JP2014114294A (ja) 2007-06-27 2014-01-08 ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
JP2015115431A Pending JP2015212270A (ja) 2007-06-27 2015-06-08 ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
JP2016226503A Withdrawn JP2017079745A (ja) 2007-06-27 2016-11-22 ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
JP2018245439A Withdrawn JP2019088288A (ja) 2007-06-27 2018-12-27 ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
JP2021086283A Pending JP2021152017A (ja) 2007-06-27 2021-05-21 ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
JP2022172896A Pending JP2023015158A (ja) 2007-06-27 2022-10-28 ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2014001373A Pending JP2014114294A (ja) 2007-06-27 2014-01-08 ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
JP2015115431A Pending JP2015212270A (ja) 2007-06-27 2015-06-08 ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
JP2016226503A Withdrawn JP2017079745A (ja) 2007-06-27 2016-11-22 ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
JP2018245439A Withdrawn JP2019088288A (ja) 2007-06-27 2018-12-27 ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
JP2021086283A Pending JP2021152017A (ja) 2007-06-27 2021-05-21 ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
JP2022172896A Pending JP2023015158A (ja) 2007-06-27 2022-10-28 ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用

Country Status (11)

Country Link
US (3) US9931377B2 (cg-RX-API-DMAC7.html)
EP (3) EP2173378B1 (cg-RX-API-DMAC7.html)
JP (7) JP2010531878A (cg-RX-API-DMAC7.html)
AU (1) AU2008269032B2 (cg-RX-API-DMAC7.html)
CA (1) CA2691785C (cg-RX-API-DMAC7.html)
DK (1) DK2173378T3 (cg-RX-API-DMAC7.html)
ES (2) ES2466916T3 (cg-RX-API-DMAC7.html)
HK (1) HK1198421A1 (cg-RX-API-DMAC7.html)
IL (1) IL202997A (cg-RX-API-DMAC7.html)
NZ (4) NZ703668A (cg-RX-API-DMAC7.html)
WO (1) WO2009002562A2 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525881A (ja) * 2013-05-14 2016-09-01 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 改変キメラ抗原受容体（ｃａｒ）ｔ細胞のヒト応用
JP2018537989A (ja) * 2015-12-18 2018-12-27 オンコセック メディカル インコーポレイテッド 異種タンパク質発現のためのプラスミド構築物及びその使用方法
JP2019533449A (ja) * 2016-10-21 2019-11-21 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５に基づく分子
JP2021518408A (ja) * 2018-03-19 2021-08-02 マルチビア インコーポレイテッド 癌治療のための、癌抑制遺伝子治療法及びｃｄ１２２／ｃｄ１３２アゴニストを含む、方法及び組成物

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3805245A1 (en) 2005-05-17 2021-04-14 University of Connecticut Compositions and methods for immunomodulation in an organism
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
NZ595736A (en) 2005-12-02 2013-05-31 Sinai School Medicine Chimeric viruses presenting non-native surface proteins and uses thereof
BRPI0707106B1 (pt) 2006-01-13 2022-06-07 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Polinucleotídeo interleucina-15, vetor de expressão, e, composição farmacêutica
JP5501222B2 (ja) 2007-05-11 2014-05-21 アルター・バイオサイエンス・コーポレーション 融合分子及びｉｌ−１５変異体
US9931377B2 (en) 2007-06-27 2018-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cell expressing complexes of IL-15 and IL-15Ralpha
US8871191B2 (en) 2009-08-14 2014-10-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 preparations to treat lymphopenia
KR20120093163A (ko) * 2009-09-14 2012-08-22 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｉｌ-15 수용체 알파 및/또는 이를 인코딩하는 핵산 분자를 포함하는 백신 및 면역 치료제, 및 이를 이용하는 방법
CN101837123B (zh) * 2010-05-27 2016-05-25 四川大学 肿瘤细胞疫苗及其制备方法
EP2918607B1 (en) 2010-09-21 2017-11-08 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
CA2815000C (en) * 2010-10-22 2024-05-21 Dana-Farber Cancer Institute, Inc. Discovery of regulatory t cells programmed to suppress an immune response
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
EP3825405A1 (en) * 2012-06-08 2021-05-26 Alkermes Pharma Ireland Limited Ligands modified by circular permutation as agonists and antagonists
US10548957B2 (en) 2012-09-28 2020-02-04 Dana-Farber Cancer Institute, Inc. Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis
MX365527B (es) * 2012-10-24 2019-06-06 Us Health Formas il-15r alfa, celulas que expresan las formas de il-15 alfa, y usos terapeuticos de il-15r alfa y complejos il-15/il-15r.
KR102222157B1 (ko) 2013-03-14 2021-03-03 이칸 스쿨 오브 메디슨 엣 마운트 시나이 뉴캐슬병 바이러스 및 이의 용도
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
KR102539359B1 (ko) 2013-04-19 2023-06-02 싸이튠 파마 감소된 혈관 누출 증후군에 대한 사이토카인 유도체 치료
KR20220148304A (ko) * 2013-08-08 2022-11-04 싸이튠 파마 병용 약학 조성물
SI3030575T1 (sl) 2013-08-08 2018-11-30 Cytune Pharma Modulokini na osnovi IL-15 in IL-15R-alfa sushi domene
CN105189562B (zh) 2014-01-08 2019-08-16 上海恒瑞医药有限公司 Il-15异源二聚体蛋白及其用途
RU2753965C2 (ru) 2014-02-14 2021-08-24 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Химерные антигенные рецепторы и способы их получения
SG11201607130RA (en) 2014-02-27 2016-09-29 Viralytics Ltd Combination method for treatment of cancer
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
US20170335281A1 (en) 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
PL3888674T3 (pl) 2014-04-07 2024-09-23 Novartis Ag Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
CN106659775B (zh) 2014-06-30 2021-08-06 阿尔托生物科学有限公司 基于il-15的分子及其方法和用途
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
KR102612313B1 (ko) 2014-07-21 2023-12-12 노파르티스 아게 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
US10851149B2 (en) 2014-08-14 2020-12-01 The Trustees Of The University Of Pennsylvania Treatment of cancer using GFR α-4 chimeric antigen receptor
WO2016028896A1 (en) 2014-08-19 2016-02-25 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
BR112017005390A2 (pt) 2014-09-17 2017-12-12 Novartis Ag células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EA201790834A1 (ru) 2014-10-14 2018-01-31 Новартис Аг Молекулы антител к pd-l1 и их применение
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
KR102609197B1 (ko) * 2014-12-19 2023-12-05 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 인터류킨 15 단백질 복합체 및 그의 용도
HRP20220893T1 (hr) 2015-04-08 2022-10-14 Novartis Ag Cd20 terapije, cd22 terapije, i kombinirane terapije sa stanicom koja eksprimira cd19 kimerni antigenski receptor
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN108025051B (zh) 2015-07-29 2021-12-24 诺华股份有限公司 包含抗pd-1抗体分子的联合疗法
HUE055469T2 (hu) 2015-07-29 2021-11-29 Novartis Ag A LAG-3 elleni antitest molekulákat tartalmazó kombinált terápiák
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US9724393B2 (en) 2015-10-06 2017-08-08 The Wistar Institute Of Anatomy And Biology Method for treatment of metastatic and refractory cancers and tumors with an inducer that overcomes inhibition of T cell proliferation
JP2019503349A (ja) 2015-12-17 2019-02-07 ノバルティス アーゲー Ｐｄ−１に対する抗体分子およびその使用
MA44140A (fr) 2015-12-22 2021-05-19 Dana Farber Cancer Inst Inc Récepteur d'antigène chimérique (car) contre la mésothéline et anticorps contre l'inhibiteur de pd-l1 pour une utilisation combinée dans une thérapie anticancéreuse
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
CN109715207B (zh) 2016-03-29 2023-03-31 南加利福尼亚大学 靶向癌症的嵌合抗原受体
WO2017173367A2 (en) 2016-03-31 2017-10-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Extracellular vesicles, methods of making them, and methods of reducing liver uptake of extracellular vesicles
EP3443001B1 (en) 2016-04-11 2025-04-30 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
JP2019519516A (ja) 2016-05-18 2019-07-11 モデルナティーエックス， インコーポレイテッド がんの治療のためのｍＲＮＡ併用療法
AU2017283480A1 (en) 2016-06-13 2019-01-24 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
EP3487878A4 (en) 2016-07-20 2020-03-25 University of Utah Research Foundation CAR-T CD229 LYMPHOCYTES AND METHODS OF USE
ES2972406T3 (es) 2016-08-01 2024-06-12 Virogin Biotech Canada Ltd Vectores del virus oncolítico del herpes simple que expresan moléculas estimuladoras del sistema inmunitario
CA3039646A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
PE20240950A1 (es) 2016-10-14 2024-05-06 Xencor Inc PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
CN110462040A (zh) 2017-01-10 2019-11-15 英特拉克森公司 通过新基因开关表达系统调节多肽的表达
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
US10743996B2 (en) * 2017-03-24 2020-08-18 Robert L. Bundy Amnion putty for cartilage repair
KR20240059648A (ko) 2017-04-19 2024-05-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 조작된 항원 수용체를 발현하는 면역 세포
EP3615003A4 (en) 2017-04-24 2021-05-26 University Of Massachusetts Lowell DIAGNOSIS AND TREATMENT OF VITILIGO
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US12338458B2 (en) 2017-05-25 2025-06-24 Memorial Sloan Kettering Cancer Center Use of the IL-15/IL-15Rα complex in the generation of antigen-specific T cells for adoptive immunotherapy
EP3630132A1 (en) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
US20220225597A1 (en) 2017-06-29 2022-07-21 Juno Therapeutics, Inc. Mouse model for assessing toxicities associated with immunotherapies
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
EP3678701A4 (en) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. THERAPEUTIC PROTEIN COMPOSITIONS AND METHODS FOR PREPARING AND USING THE SAME
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
PL3703750T3 (pl) 2017-11-01 2025-04-07 Juno Therapeutics, Inc. Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy
CA3080904A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
EP3724225A1 (en) 2017-12-15 2020-10-21 Juno Therapeutics, Inc. Anti-cct5 binding molecules and methods of use thereof
CN111918661A (zh) 2018-02-21 2020-11-10 得克萨斯大学体系董事会 用于活化和扩增自然杀伤细胞的方法及其用途
RU2020132924A (ru) * 2018-03-08 2022-04-11 Рубиус Терапьютикс, Инк. Терапевтические клеточные системы и способы лечения рака и инфекционных заболеваний
WO2019195420A1 (en) * 2018-04-04 2019-10-10 Nant Holding IP, LLC Advanced avartar dendritic cells
CN112867734A (zh) 2018-04-18 2021-05-28 Xencor股份有限公司 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
IL278090B2 (en) 2018-04-18 2024-07-01 Xencor Inc Il-15/il-15rα heterodimeric fc fusion proteins and uses thereof
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
EP3806962A1 (en) 2018-06-13 2021-04-21 Novartis AG Bcma chimeric antigen receptors and uses thereof
CA3102821A1 (en) 2018-06-22 2019-12-26 Cugene Inc. Novel interleukin-15 (1l-15) fusion proteins and uses thereof
KR20210038548A (ko) 2018-06-22 2021-04-07 큐진 인크. 사이토카인-기반 생체활성 약물 및 이의 사용 방법
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
CN113015540A (zh) * 2018-09-14 2021-06-22 莫得纳特斯公司 使用mrna治疗剂治疗癌症的方法和组合物
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
WO2020077180A1 (en) 2018-10-11 2020-04-16 Nantcell, Inc. Treatment of immunosuppressed subjects
MA53862A (fr) 2018-10-12 2022-01-19 Xencor Inc Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci
MA54079A (fr) 2018-11-01 2021-09-08 Juno Therapeutics Inc Récepteurs antigéniques chimériques spécifiques du gprc5d (élément d du groupe 5 de classe c des récepteurs couplés à la protéine g)
SG11202104188VA (en) 2018-11-01 2021-05-28 Juno Therapeutics Inc Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
EP3880238A1 (en) 2018-11-16 2021-09-22 Juno Therapeutics, Inc. Methods of dosing engineered t cells for the treatment of b cell malignancies
CA3119801A1 (en) * 2018-11-29 2020-06-04 William Jia Hsv vector with reduced neurotoxicity
PL3886875T3 (pl) 2018-11-30 2024-09-09 Juno Therapeutics, Inc. Metody leczenia z wykorzystaniem adoptywnej terapii komórkowej
EP3897853A1 (en) 2018-12-20 2021-10-27 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
BR112021014833A2 (pt) 2019-01-29 2021-10-05 Juno Therapeutics, Inc. Anticorpos e receptores antigênicos quiméricos específicos para receptor órfão 1 de tipo tirosina quinase de receptor (ror1)
US20220226402A1 (en) * 2019-03-25 2022-07-21 Northshore University Health System Methods and compositions comprising enhanced targeted immune gene therapy for the treatment of cancer
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
KR20230009386A (ko) 2020-04-10 2023-01-17 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
CN116635062A (zh) 2020-11-13 2023-08-22 诺华股份有限公司 使用表达嵌合抗原受体（car）的细胞的组合疗法
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
US12234473B2 (en) 2020-12-31 2025-02-25 Immatics US, Inc. CD8 polypeptides, compositions, and methods of using thereof
KR20230160294A (ko) 2021-03-24 2023-11-23 알케르메스, 인코포레이티드 Upar 항체 및 이를 갖는 융합 단백질
CN119546638A (zh) 2022-06-22 2025-02-28 朱诺治疗学股份有限公司 用于cd19靶向的car t细胞的二线疗法的治疗方法
AU2023317825A1 (en) 2022-08-04 2025-02-13 Novartis Pharma Ag Il-15 inhibitors useful for the treatment of atopic dermatitis
JP2025525937A (ja) 2022-08-05 2025-08-07 ジュノー セラピューティクス インコーポレイテッド Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体
WO2024040132A2 (en) 2022-08-16 2024-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Synergistic interactions for improved cancer treatment
CN120712102A (zh) 2022-12-13 2025-09-26 朱诺治疗学股份有限公司 对baff-r和cd19具特异性的嵌合抗原受体及其方法和用途
WO2025019869A2 (en) * 2023-07-20 2025-01-23 The Johns Hopkins University Cell culture medium and compositions thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62205784A (ja) * 1986-03-05 1987-09-10 雪印乳業株式会社 新しい型のプラスミノ−ゲン活性化因子の製造方法
JPH07255470A (ja) * 1994-03-17 1995-10-09 Snow Brand Milk Prod Co Ltd 無血清培地およびこれを用いた物質生産方法
JP2003522732A (ja) * 1998-12-22 2003-07-29 マリン ポリマー テクノロジーズ，インコーポレーテッド 細胞増殖性疾患を治療するための方法および組成物
US20060165668A1 (en) * 2004-12-10 2006-07-27 Liu Linda N Genetically modified tumor cells as cancer vaccines

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2444713A1 (fr) 1978-12-18 1980-07-18 Pasteur Institut Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
JPS6297624A (ja) 1985-10-24 1987-05-07 イ−・アイ・デユポン・デ・ニモアス・アンド・カンパニ− ガス分離法及びその膜
US4705540A (en) 1986-04-17 1987-11-10 E. I. Du Pont De Nemours And Company Polyimide gas separation membranes
US4717394A (en) 1986-10-27 1988-01-05 E. I. Du Pont De Nemours And Company Polyimide gas separation membranes
US4717393A (en) 1986-10-27 1988-01-05 E. I. Du Pont De Nemours And Company Polyimide gas separation membranes
US4912197A (en) 1987-08-14 1990-03-27 E. I. Du Pont De Nemours And Company Highly soluble clear polyimides
US4880442A (en) 1987-12-22 1989-11-14 E. I. Du Pont De Nemours And Company Polyimide gas separation membranes
US4935490A (en) 1988-04-13 1990-06-19 E. I. Dupont De Nemours And Company Highly soluble aromatic polyimides
US4838900A (en) 1988-04-13 1989-06-13 E. I. Du Pont De Nemours And Company Polyimide gas separation membranes
US4851505A (en) 1988-04-13 1989-07-25 E. I. Du Pont De Nemours And Company Highly soluble aromatic polyimides
US4863496A (en) 1988-04-13 1989-09-05 E. I. Du Pont De Nemours And Co. Reactive posttreatment for gas separation membranes
US4961539A (en) 1989-08-01 1990-10-09 Deem K Michael Truck-mounted pallet chipper
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE4135070C1 (cg-RX-API-DMAC7.html) 1991-10-24 1993-05-19 Institut Fuer Rundfunktechnik Gmbh, 8000 Muenchen, De
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5552303A (en) * 1993-03-08 1996-09-03 Immunex Corporation DNA encoding epithelium-derived T-cell factor
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US5624679A (en) 1993-12-01 1997-04-29 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers
US5622834A (en) 1993-12-01 1997-04-22 Marine Polymer Technologies, Inc. Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture
US5686115A (en) 1993-12-01 1997-11-11 Marine Polymer Technologies, Inc. Poly-β-1→4-N-acetylucosamine copolymer composition with collagen
US5858350A (en) * 1993-12-01 1999-01-12 Marine Polymer Technologies Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system
DK0772624T3 (da) 1994-04-06 2000-11-13 Immunex Corp Interleukin-15
US5591630A (en) 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
US6548065B1 (en) * 1994-05-06 2003-04-15 Immunex Corporation Interleukin-15 receptors
US20020127201A1 (en) * 1994-07-01 2002-09-12 Dana-Farber Cancer Institute. Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chain
US7008624B1 (en) * 1995-02-22 2006-03-07 Immunex Corporation Antagonists of interleukin-15
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
DE19608813C2 (de) * 1996-03-07 1998-07-02 Angewandte Gentechnologie Syst Konjugat zur Beeinflussung von Wechselwirkungen zwischen Proteinen
US6451308B1 (en) * 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
DE69733610T2 (de) * 1996-04-26 2006-05-11 Beth Israel Deaconess Medical Center, Inc., Boston Interleukin-15 antagonisten
DK1273304T4 (da) * 1997-02-21 2009-08-31 Amgen Inc Anvendelse af interleukin-15
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
US20040170604A1 (en) * 1998-07-06 2004-09-02 Tosoh Corporation IL-6 receptor IL-6 direct fusion protein
CA2401652A1 (en) 2000-03-01 2001-09-07 Medimmune, Inc. High potency recombinant antibodies and method for producing them
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
US20020022030A1 (en) * 2000-04-26 2002-02-21 Philippa Marrack Product and process for regulation of T cell responses
EP1349873B1 (en) 2000-09-14 2009-04-01 Beth Israel Deaconess Medical Center, Inc. Modulation of il-2- and il-15-mediated t cell responses
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7041657B2 (en) 2001-02-12 2006-05-09 Marine Polymer Technologies Inc. Compositions and methods for modulation of vascular structure and/or function
US7638604B2 (en) * 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
AU2002250236A1 (en) 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
GB0209893D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
EP1575509B1 (en) 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
ATE525398T1 (de) 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
CA2510309C (en) 2002-12-16 2014-09-16 Liyange P. Perera Recombinant vaccine viruses expressing il-15 and methods of using the same
DE10260805A1 (de) 2002-12-23 2004-07-22 Geneart Gmbh Verfahren und Vorrichtung zum Optimieren einer Nucleotidsequenz zur Expression eines Proteins
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
AU2004214932B2 (en) 2003-02-24 2009-12-03 Marine Polymer Technologies, Inc. Cell-polymer fiber compositions and use thereof
JPWO2005023289A1 (ja) 2003-09-08 2007-11-01 株式会社インテレクチャル・プロパティ・コンサルティング 慢性ｃ型肝炎を治療するための医薬組成物
US7435596B2 (en) * 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
ATE516305T1 (de) 2004-02-27 2011-07-15 Inst Nat Sante Rech Med Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten
AR050693A1 (es) * 2004-08-11 2006-11-15 Zheng Xin Xiao Composiciones que contienen interleuquina-15 mutante y supresion de una respuesta inmune.
JP2008515896A (ja) * 2004-10-05 2008-05-15 オクスナー クリニック ファウンデーション Ｉｌ−１５によるｂ細胞増殖の増強
AU2005306356A1 (en) 2004-11-19 2006-05-26 Biogen Idec Ma Inc. Methods for producing mammalian cells
KR20070108402A (ko) 2005-02-15 2007-11-09 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 화학요법제와 ｉｌ-2 및 선택적으로 항-ｃｄ20 항체의조합물을 사용하여 임파종을 치료하는 방법
US20060257361A1 (en) * 2005-04-12 2006-11-16 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Novel form of interleukin-15, Fc-IL-15, and methods of use
EP3805245A1 (en) * 2005-05-17 2021-04-14 University of Connecticut Compositions and methods for immunomodulation in an organism
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
WO2007070488A2 (en) 2005-12-12 2007-06-21 The Cbr Institute For Biomedical Research, Inc. Integrin alpha l i domain mutants with increased binding affinity
US20070160578A1 (en) * 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
BRPI0707106B1 (pt) 2006-01-13 2022-06-07 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Polinucleotídeo interleucina-15, vetor de expressão, e, composição farmacêutica
SG170001A1 (en) 2006-02-16 2011-04-29 Nascent Biolog Inc Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject
US8586055B2 (en) 2007-01-12 2013-11-19 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA immunization protocols
JP5501222B2 (ja) * 2007-05-11 2014-05-21 アルター・バイオサイエンス・コーポレーション 融合分子及びｉｌ−１５変異体
US9931377B2 (en) 2007-06-27 2018-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cell expressing complexes of IL-15 and IL-15Ralpha
US8871191B2 (en) 2009-08-14 2014-10-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of IL-15 preparations to treat lymphopenia
EP2918607B1 (en) 2010-09-21 2017-11-08 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62205784A (ja) * 1986-03-05 1987-09-10 雪印乳業株式会社 新しい型のプラスミノ−ゲン活性化因子の製造方法
JPH07255470A (ja) * 1994-03-17 1995-10-09 Snow Brand Milk Prod Co Ltd 無血清培地およびこれを用いた物質生産方法
JP2003522732A (ja) * 1998-12-22 2003-07-29 マリン ポリマー テクノロジーズ，インコーポレーテッド 細胞増殖性疾患を治療するための方法および組成物
US20060165668A1 (en) * 2004-12-10 2006-07-27 Liu Linda N Genetically modified tumor cells as cancer vaccines

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6013029390; Ｐｒｏｃ．　Ｎａｔｌ．　Ａｃａｄ．　Ｓｃｉ．　ＵＳＡ，　２００７．０１，　Ｖｏｌ．１０４，　Ｎｏ．２，　ｐｐ．５８８-５９３ *
JPN6013029391; Ｊ．　Ｂｉｏｌ．　Ｃｈｅｍ．，　２００６，　Ｖｏｌ．２８１，　Ｎｏ．３，　ｐｐ．１６１２-１６１９ *
JPN6013029393; Ｐｒｏｃ．　Ｎａｔｌ．　Ａｃａｄ．　Ｓｃｉ．　ＵＳＡ，　２００６，　Ｖｏｌ．１０３，　Ｎｏ．２４，　ｐｐ．９１６６-９１７１ *
JPN6014026731; Ｉｍｍｕｎｉｔｙ，　２００２，　Ｖｏｌ．１７，　ｐｐ．５３７-５４７ *
JPN6015004476; バイオテクノロジージャーナル，　２００７．０３-０４，　ｐｐ．２３４-２３５ *
JPN6015004478; Ｉｎｔ．　Ｊ．　Ｃａｎｃｅｒ，　１９９２，　Ｖｏｌ．５０，　ｐｐ．１５３-１６０ *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525881A (ja) * 2013-05-14 2016-09-01 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 改変キメラ抗原受容体（ｃａｒ）ｔ細胞のヒト応用
JP2019047830A (ja) * 2013-05-14 2019-03-28 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 改変キメラ抗原受容体（ｃａｒ）ｔ細胞のヒト応用
JP2018537989A (ja) * 2015-12-18 2018-12-27 オンコセック メディカル インコーポレイテッド 異種タンパク質発現のためのプラスミド構築物及びその使用方法
JP7079729B2 (ja) 2015-12-18 2022-06-02 オンコセック メディカル インコーポレイテッド 異種タンパク質発現のためのプラスミド構築物及びその使用方法
JP2022116129A (ja) * 2015-12-18 2022-08-09 オンコセック メディカル インコーポレイテッド 異種タンパク質発現のためのプラスミド構築物及びその使用方法
US11713467B2 (en) 2015-12-18 2023-08-01 Oncosec Medical Incorporated Plasmid constructs for heterologous protein expression and methods of use
JP2019533449A (ja) * 2016-10-21 2019-11-21 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５に基づく分子
JP7492336B2 (ja) 2016-10-21 2024-05-29 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ－１５に基づく分子
JP2021518408A (ja) * 2018-03-19 2021-08-02 マルチビア インコーポレイテッド 癌治療のための、癌抑制遺伝子治療法及びｃｄ１２２／ｃｄ１３２アゴニストを含む、方法及び組成物
US12454561B2 (en) 2018-03-19 2025-10-28 Multivir Inc. Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer

Also Published As

Publication number Publication date
US11110150B2 (en) 2021-09-07
WO2009002562A2 (en) 2008-12-31
HK1143084A1 (en) 2010-12-24
DK2173378T3 (da) 2014-05-12
IL202997A (en) 2017-06-29
US20190290734A1 (en) 2019-09-26
NZ582330A (en) 2012-05-25
JP2023015158A (ja) 2023-01-31
EP2173378A4 (en) 2010-09-29
EP2724728B1 (en) 2018-10-17
HK1198421A1 (en) 2015-04-24
EP2173378B1 (en) 2014-03-19
IL202997A0 (en) 2011-08-01
US9931377B2 (en) 2018-04-03
NZ599338A (en) 2013-11-29
EP2724727A1 (en) 2014-04-30
JP2014114294A (ja) 2014-06-26
US20170151310A1 (en) 2017-06-01
ES2716476T3 (es) 2019-06-12
EP2173378A2 (en) 2010-04-14
WO2009002562A3 (en) 2009-02-26
NZ703668A (en) 2016-07-29
US10265382B2 (en) 2019-04-23
JP2019088288A (ja) 2019-06-13
NZ616254A (en) 2015-04-24
ES2466916T3 (es) 2014-06-11
CA2691785A1 (en) 2008-12-31
US20110081311A1 (en) 2011-04-07
CA2691785C (en) 2017-01-10
EP2724728A1 (en) 2014-04-30
JP2015212270A (ja) 2015-11-26
AU2008269032A1 (en) 2008-12-31
AU2008269032B2 (en) 2013-12-05
JP2021152017A (ja) 2021-09-30
JP2017079745A (ja) 2017-05-18

Similar Documents

Publication Publication Date Title
JP2023015158A (ja) ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
JP6359019B2 (ja) ＩＬ−１５Ｒα型、ＩＬ−１５Ｒα型を発現する細胞、ならびにＩＬ−１５ＲαおよびＩＬ−１５／ＩＬ−１５Ｒα複合体の治療上の使用
JP6655061B2 (ja) 状態を治療するためのｉｌ−１５およびｉｌ−１５ｒアルファヘテロ二量体用量増加レジメン
AU2013203204B2 (en) Complexes of il-15 and il-15r.alpha and uses thereof
AU2016206235B2 (en) Complexes of il-15 and il-15ralpha and uses thereof
HK1197881A (en) Complexes of il-15 and il-15r alpha and uses thereof
HK1143084B (en) Complexes of il-15 and il-15ralpha and uses thereof
HK1197881B (en) Complexes of il-15 and il-15r alpha and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110623

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110623

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131007

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131015

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20140107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140107

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140925

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150210